Delaney Dennis R Grows Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Delaney Dennis R lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,404 shares of the medical instruments supplier’s stock after purchasing an additional 55 shares during the period. Delaney Dennis R’s holdings in Becton, Dickinson and Company were worth $2,327,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of BDX. Norges Bank purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth $761,798,000. Nordea Investment Management AB lifted its position in Becton, Dickinson and Company by 277.3% in the first quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock valued at $478,295,000 after acquiring an additional 1,423,353 shares during the last quarter. Vanguard Group Inc. lifted its position in Becton, Dickinson and Company by 2.0% in the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock valued at $6,703,041,000 after acquiring an additional 516,427 shares during the last quarter. Cooke & Bieler LP lifted its position in Becton, Dickinson and Company by 117.1% in the fourth quarter. Cooke & Bieler LP now owns 710,932 shares of the medical instruments supplier’s stock valued at $173,347,000 after acquiring an additional 383,485 shares during the last quarter. Finally, First Trust Advisors LP lifted its position in Becton, Dickinson and Company by 880.8% in the fourth quarter. First Trust Advisors LP now owns 294,082 shares of the medical instruments supplier’s stock valued at $71,706,000 after acquiring an additional 264,097 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Becton, Dickinson and Company news, EVP Roland Goette sold 3,300 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total value of $781,209.00. Following the sale, the executive vice president now owns 11,308 shares of the company’s stock, valued at $2,676,942.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the sale, the executive vice president now directly owns 5,381 shares in the company, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,615 shares of company stock worth $2,033,381. 0.31% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of recent research reports. Evercore ISI dropped their price objective on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. The Goldman Sachs Group initiated coverage on shares of Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 price objective on the stock. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 27th. Citigroup dropped their price objective on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research note on Wednesday. Finally, Barclays lifted their price objective on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research note on Monday, May 6th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $280.14.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock traded up $1.13 on Thursday, reaching $225.00. 1,849,424 shares of the stock were exchanged, compared to its average volume of 1,433,974. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $287.32. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The business has a fifty day moving average price of $233.03 and a two-hundred day moving average price of $237.02. The firm has a market capitalization of $65.03 billion, a PE ratio of 49.56, a PEG ratio of 1.97 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, topping the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The company had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. During the same period in the prior year, the business posted $2.86 earnings per share. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, research analysts anticipate that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 28th. Shareholders of record on Monday, June 10th were given a dividend of $0.95 per share. The ex-dividend date of this dividend was Monday, June 10th. This represents a $3.80 annualized dividend and a yield of 1.69%. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.